Drs. Peter Block and Jonas Oldgren review the RE-DUAL PCI trial which examined dual anithrombotic therapy with dabigatran in AFib patients undergoing PCI.

Keywords: AHA Annual Scientific Sessions, AHA17, Antithrombins, Fibrinolytic Agents, Atrial Fibrillation, Percutaneous Coronary Intervention, Cardiovascular Diseases

< Back to Listings